TRCT
NDRM

Tower Research Capital (TRC)’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Tower Research Capital (TRC)’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-264
Closed -$10K – 4521
2017
Q3 		$10K Buy
+264
New +$9.71K ﹤0.01% 3101
2016
Q2 		– Sell
-341
Closed -$5K – 5586
2016
Q1 		$5K Buy
+341
New +$4.61K ﹤0.01% 2834
2015
Q4 		– Sell
-581
Closed -$12K – 5771
2015
Q3 		$12K Buy
+581
New +$11.9K ﹤0.01% 2205
2015
Q1 		– Sell
-500
Closed -$7K – 5603
2014
Q4 		$7K Buy
+500
New +$3.95K ﹤0.01% 2550

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Tower Research Capital (TRC)'s NDRM Position: Q4 2017 in Review

Tower Research Capital (TRC) sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 264 shares — an estimated $10K sold.

Tower Research Capital (TRC) first reported a position in NDRM in Q4 2014 and held it in 4 quarters. The position peaked at $12K in Q3 2015. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Tower Research Capital (TRC) reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 264 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $10K.
  • Tower Research Capital (TRC) first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s NeuroDerm Ltd. Ordinary Shares position peaked at $12K in Q3 2015.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2017, filed 9 Feb 2018.